Ampersand provides more data to back InPath test
This article was originally published in Clinica
Executive Summary
Further evidence that Ampersand Medical's InPath slide-based test outperforms conventional Pap screening for cervical cancer was presented at the 14th International Congress of Cytology in Amsterdam, the Netherlands, at the end of May. Matthew Gombrich, senior scientist at Chicago, Illinois-based Ampersand, told delegates that in a study of 45 samples, the InPath test demonstrated 100% accuracy for detecting high-grade squamous intraepithelial lesions.